

19 October 2011

Etisalat

9MFY11 results on track

Buy

Target price
Dh12.89


Price
Dh9.99

Short term (0-60 days)
n/a

Market view
No Weighting

Price performance

	(1M)	(3M)	(12M)
Price (Dh)	10.30	10.90	11.55
Absolute (%)	-3.0	-8.3	-13.5
Rel market (%)	4.9	3.5	10.8
Rel sector (%)	5.3	3.1	-5.8



Market capitalisation
Dh78.98bn (€15.65bn)

Average (12M) daily turnover
Dh15.04m (US\$4.12m)

Sector: DFM Telecoms
RIC: ETEL.DU, ETISALAT.UH
Priced Dh9.99 at close 18 Oct 2011.
Source: Bloomberg

Etisalat's 9MFY11 results (period end Sept-11) revealed an 8.4% yoy decline in net profit despite a 2.9% yoy increase in consolidated revenue, in line with our forecasts for the full year. No change to our estimates; maintain Buy and Dh12.89 target price on 29% upside and healthy 6% yield.

Key forecasts

	FY09A	FY10A	FY11F	FY12F	FY13F
Revenue (Dhm)	30,831	31,929	32,578	34,390	36,021
EBITDA (Dhm)	11,349	9,981	9,906	10,256	12,266
Reported net profit (Dhm)	8,836	7,631	6,983	7,344	9,329
Normalised net profit (Dhm)	8,836	7,631	6,983	7,344	9,329
Normalised EPS (Dh)	1.12	0.97	0.88	0.93	1.18
Dividend per share (Dh)	0.55	0.60	0.60	0.60	0.60
Dividend yield (%)	5.46	6.01	6.01	6.01	6.01
Normalised PE (x)	8.94	10.35	11.31	10.75	8.47
EV/EBITDA (x)	6.36	7.52	7.51	6.88	5.25
EV/invested capital (x)	2.15	1.94	1.86	1.82	1.74
ROIC - WACC (%)	0.00	0.00	0.00	0.00	0.00

Accounting standard: IFRS

Source: Company data, Rasmala forecasts

year to Dec, fully diluted

9MFY11 consolidated revenue of Dh24bn is on track to achieve our full-year estimates

Revenue growth at the end of 9MFY11 came in at 2.9% yoy with Etisalat posting consolidated revenue of Dh24bn. The main reason for the relatively weak top-line growth was a decline in the performance of its UAE segment of operations, which constitutes the bulk of Etisalat's consolidated revenue base. Revenue from the UAE declined by 0.8% yoy to reach Dh17.9bn at the end of 9MFY11, contributing 75% of total revenues versus 78% at the end of 9MFY10. We attribute the UAE slowdown to mobile subscriber market share losses to competitor, Du. According to Du, which posts UAE mobile market share statistics, Etisalat's active mobile market share slid to 56.4% at the end of June 2011 from 59.8% at the end of December 2010.

Net profit declined 8.4% yoy to Dh5.1bn; we estimate full year dividend yield at 6%

As a result of both higher operating expenses and lower net finance income at the end of 9MFY11, net profit declined 8.4% yoy to reach Dh5.1bn compared to Dh5.6bn at the end of 9MFY10. We believe Etisalat is losing focus on its core market, the UAE, which is its cash cow. We factor this into our forecasts, but see upside potential if Etisalat should reduce its cost base in the UAE to make itself more competitive against Du. Separately, Etisalat also declared the first interim dividend for FY11 at Dh0.25 per share; we expect total dividend distribution of Dh0.60 per share for FY11, an estimated dividend yield of 6%.

Maintain estimates, Buy recommendation and target price of Dh12.89

In general, Etisalat's 9MFY11 financial results are consistent with our FY11 estimates. We currently estimate that revenue for FY11 will grow 2.0% yoy, while net profit declines 8.5% yoy. Thus, we are not changing our estimates for Etisalat and we maintain our target price of Dh12.89 with a Buy recommendation based on upside potential of c29% and a healthy cash dividend yield estimate of 6% for FY11.

Important disclosures can be found in the Disclosures Appendix.

Distributed outside MENA by The Royal Bank of Scotland N.V. and its affiliates under a strategic alliance with Rasmala Investment Bank Ltd.

Analyst

Shrouk Diab
United Arab Emirates
+971 552 248 033
shrouk.diab@rasmala.com

Dubai International Financial Centre,
The Gate Village, Building 10, Level 1,
P.O. Box 31145, Dubai, United Arab
Emirates

www.rasmala.com

Income statement

Dhm	FY09A	FY10A	FY11F	FY12F	FY13F
Revenue	30831	31929	32578	34390	36021
Cost of sales	-3840	-3760	-4058	-4284	-4487
Operating costs	-15642	-18189	-18614	-19850	-19268
EBITDA	11349	9981	9906	10256	12266
DDA & Impairment (ex gw)	-2535	-2985	-3505	-3291	-3183
EBITA	8815	6996	6401	6965	9083
Goodwill (amort/impaird)	0.00	0.00	0.00	0.00	0.00
EBIT	8815	6996	6401	6965	9083
Net interest	11.6	532.7	503.3	338.7	260.2
Associates (pre-tax)	0.00	0.00	0.00	0.00	0.00
Other pre-tax items	0.00	0.00	0.00	0.00	0.00
Reported PTP	8827	7529	6904	7304	9344
Taxation	-243.8	-100.4	-92.1	-97.4	-124.6
Minority interests	253.6	202.0	171.7	137.3	109.9
Other post-tax items	0.00	-0.00	0.00	0.00	-0.00
Reported net profit	8836	7631	6983	7344	9329
Tot normalised items	0.00	0.00	0.00	0.00	0.00
Normalised EBITDA	11349	9981	9906	10256	12266
Normalised PTP	8827	7529	6904	7304	9344
Normalised net profit	8836	7631	6983	7344	9329

Source: Company data, Rasmala forecasts

year to Dec

Balance sheet

Dhm	FY09A	FY10A	FY11F	FY12F	FY13F
Cash & market secs (1)	11309	10277	8388	8958	14931
Other current assets	8253	9037	9437	9611	9831
Tangible fixed assets	17585	20675	22052	22165	21877
Intang assets (incl gw)	16778	15550	14573	13541	12461
Oth non-curr assets	17452	20068	19904	20483	21322
Total assets	71379	75607	74353	74758	80421
Short term debt (2)	1079	1195	0.00	0.00	0.00
Trade & oth current liab	22409	23283	25160	22941	24295
Long term debt (3)	3422	5205	574.8	337.7	100.5
Oth non-current liab	4079	3359	3985	4383	4454
Total liabilities	30989	33042	29720	27662	28850
Total equity (incl min)	40389	42565	44633	47096	51572
Total liab & sh equity	71379	75607	74353	74758	80421
Net debt	-6808	-3877	-4586	-8383	-14593

Source: Company data, Rasmala forecasts

year ended Dec

Cash flow statement

Dhm	FY09A	FY10A	FY11F	FY12F	FY13F
EBITDA	11349	9981	9906	10256	12266
Change in working capital	-153.6	-2846	1186	617.2	1134
Net interest (pd) / rec	193.4	532.7	503.3	338.7	260.2
Taxes paid	-86.0	-100.4	-92.1	-97.4	-124.6
Other oper cash items	-985.1	202.0	171.7	137.3	109.9
Cash flow from ops (1)	10318	7769	11675	11252	13646
Capex (2)	-6798	-4853	-3904	-2372	-1814
Disposals/(acquisitions)	0.00	896.7	497.4	143.3	180.0
Other investing cash flow	-166.0	-473.5	164.0	-579.7	-838.7
Cash flow from invest (3)	-6964	-4430	-3243	-2808	-2473
Incr / (decr) in equity	0.00	0.00	0.00	0.00	0.00
Incr / (decr) in debt	485.9	-59.2	-5565	-3111	-453.4
Ordinary dividend paid	-3893	-4312	-4744	-4744	-4744
Preferred dividends (4)	0.00	0.00	0.00	0.00	0.00
Other financing cash flow	0.00	0.00	-11.8	-18.4	-2.99
Cash flow from fin (5)	-3407	-4372	-10321	-7873	-5200
Forex & disc ops (6)	67.7	0.00	0.00	0.00	0.00
Incr/(decr) cash (1+3+5+6)	14.3	-1032	-1889	570.3	5972
Equity FCF (1+2+4)	3520	2916	7771	8880	11831

Source: Company data, Rasmala forecasts

year to Dec

Recommendation structure

Absolute performance, long term (fundamental) recommendation: The recommendation is based on implied upside/downside for the stock from the target price and only reflects capital appreciation. A Buy/Sell implies upside/downside of 10% or more and a Hold less than 10%.

Performance parameters and horizon: Given the volatility of share prices and our pre-disposition not to change recommendations frequently, these performance parameters should be interpreted flexibly. Performance in this context only reflects capital appreciation and the horizon is 12 months.

Market or sector view: This view is the responsibility of the strategy team and a relative call on the performance of the market/sector relative to the region. Overweight/Underweight implies upside/downside of 10% or more and Neutral implies less than 10% upside/downside.

Target price: The target price is the level the stock should currently trade at if the market were to accept the analyst's view of the stock and if the necessary catalysts were in place to effect this change in perception within the performance horizon. In this way, therefore, the target price abstracts from the need to take a view on the market or sector. If it is felt that the catalysts are not fully in place to effect a re-rating of the stock to its warranted value, the target price will differ from 'fair' value.

Valuation and risks to target price

Etisalat (RIC: ETEL.DU, Rec: Buy, CP: Dh9.99, TP: Dh12.89): To arrive at our target price, we use a DCF-based sum of the parts. The two main risks to our valuation are a prolonged pricing war with Du and overpaying for licences and acquisitions.

Disclaimer

This report is prepared by Rasmala Investment Bank Limited ("RIB"). RIB is regulated by the Dubai Financial Services Authority ("DFSA"). RIB products or services are only made available to customers who RIB is satisfied meet the regulatory criteria to be a "Professional Client", as defined under the Rules and Regulations of the Dubai International Financial Centre ("DIFC").

Our investment recommendations take into account both risk and expected return. We base our long-term fair value estimates on a fundamental analysis of a company's future prospects, after having taken perceived risks into consideration. We have conducted reasonable research to arrive at our investment recommendations and fair value estimates for the company or companies mentioned in this report. Although the information in this report has been obtained from sources that RIB believes to be reliable, we have not independently verified such information thus it may not be accurate or complete. RIB does not represent or warrant, either expressly or impliedly, the accuracy or completeness of the information or opinions contained within this report and no liability whatsoever is accepted by RIB or any other person for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

Readers should understand that financial projections, fair value estimates and statements regarding future prospects may not be realized. All opinions and estimates included in this report constitute our judgment as of this date and are subject to change without notice. This research report is prepared for general circulation and is intended for general information purposes only. It is not intended as an offer or solicitation or advice with respect to the purchase or sale of any securities referred to in the report. It is not tailored to the specific investment objectives, financial situation or needs of any specific person that may receive this report. We strongly advise potential investors to seek financial guidance when determining whether an investment is appropriate to their needs.

RIB is not registered with the U.S. Securities and Exchange Commission, or any U.S. state authority, as a broker-dealer or investment advisor. This report has not been approved, disapproved or recommended by the U.S. Securities and Exchange Commission, any state securities commission in the United States, the securities commission of any non-U.S. jurisdiction or any other U.S. or non-U.S. regulatory authority. None of these authorities has passed on or endorsed the merits or the accuracy or adequacy of this report.

RIB and its group entities (together and separately, "Rasmala") does and may seek to do business with companies covered in its reports. As a result, users should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Rasmala and its respective employees, directors and officers shall not be responsible or liable for any liabilities, damages, losses, claims, causes of action, or proceedings (including without limitation indirect, consequential, special, incidental, or punitive damages) arising out of or in connection with the use of this report or any errors or omissions in its content.

The research analyst or analysts responsible for the content of this research report certify that: (1) the views expressed and attributed to the research analyst or analysts in the research report accurately reflect their personal opinion(s) about the subject securities and issuers and/or other subject matter as appropriate; and, (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views contained in this research report. On a general basis, the efficacy of recommendations is a factor in the performance appraisals of analysts.